TSH Biopharm Corporation Limited

TPEX:8432 Stock Report

Market Cap: NT$2.2b

TSH Biopharm Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Sze-Yuan Yang

Chief executive officer

n/a

Total compensation

CEO salary percentagen/a
CEO tenure6.1yrs
CEO ownershipn/a
Management average tenure1.8yrs
Board average tenure1.3yrs

Recent management updates

Recent updates

Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Feb 18
Weak Financial Prospects Seem To Be Dragging Down TSH Biopharm Corporation Limited (GTSM:8432) Stock

Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

Jan 21
Is TSH Biopharm Corporation Limited (GTSM:8432) An Attractive Dividend Stock?

TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

Dec 16
TSH Biopharm's (GTSM:8432) Shareholders Are Down 26% On Their Shares

CEO Compensation Analysis

How has Sze-Yuan Yang's remuneration changed compared to TSH Biopharm's earnings?
DateTotal CompensationSalaryCompany Earnings
Dec 31 2024n/an/a

NT$113m

Sep 30 2024n/an/a

NT$120m

Jun 30 2024n/an/a

NT$88m

Mar 31 2024n/an/a

NT$92m

Dec 31 2023n/an/a

NT$62m

Sep 30 2023n/an/a

NT$54m

Jun 30 2023n/an/a

NT$55m

Mar 31 2023n/an/a

NT$53m

Dec 31 2022n/an/a

NT$62m

Sep 30 2022n/an/a

NT$68m

Jun 30 2022n/an/a

NT$60m

Mar 31 2022n/an/a

NT$57m

Dec 31 2021NT$6mNT$4m

NT$47m

Sep 30 2021n/an/a

NT$47m

Jun 30 2021n/an/a

NT$53m

Mar 31 2021n/an/a

NT$48m

Dec 31 2020NT$6mNT$5m

NT$62m

Compensation vs Market: Insufficient data to establish whether Sze-Yuan's total compensation is reasonable compared to companies of similar size in the TW market.

Compensation vs Earnings: Sze-Yuan's compensation has been consistent with company performance over the past year.

CEO

Sze-Yuan Yang

6.1yrs

Tenure

NT$5,724,000

Compensation

Ms. Sze-Yuan Yang serves as President at TSH Biopharm Corporation Limited since January 17, 2019. She studied at Institute of Pharmacology, National Yangming University. She has served at TTY Pharmaceutica...

Leadership Team

NamePositionTenureCompensationOwnership
Sze-Yuan Yang
President6.1yrsNT$5.72mno data
Jung-Liang Kao
Senior Division Director of Finance Division & CFOless than a yearno datano data
Chen-Ju Kan
Senior Manager of the Accounting Departmentno datano datano data
Yu-Chung Wu
Senior Director of Sales1.1yrsno datano data
Chuan-Hsu Chen
Senior Director of Marketing1.8yrsno datano data
Hsin-Young Liu
Company Secretary4.8yrsno datano data

1.8yrs

Average Tenure

Experienced Management: 8432's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.

Board Members

NamePositionTenureCompensationOwnership
Chuan-Quan Lin
Chairman4.8yrsno datano data
Kang-Chi Chou
Representative Director4.8yrsno datano data
Carl Hsiao
Representative Director4.8yrsno data0.088%
NT$ 1.9m
Rwei-Syun Chen
Independent Directorno datano datano data
Yaw-Bin Huang
Independent Directorno datano datano data
Te-Yu Chou
Independent Director1.3yrsno datano data
Yong-Liang Wu
Director1.3yrsno datano data
Yuen-Liang Lai
Independent Directorless than a yearno datano data
Shiow-Ming Wu
Independent Directorless than a yearno datano data

1.3yrs

Average Tenure

Experienced Board: 8432's board of directors are not considered experienced ( 1.3 years average tenure), which suggests a new board.

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/02/28 00:17
End of Day Share Price 2025/02/27 00:00
Earnings2024/12/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

TSH Biopharm Corporation Limited is covered by 2 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Yi-hsin LeeJih Sun Securities Investment Consulting Co., Ltd.
Hsiu Chi LinMasterlink Securities Corp.